Editorial Policy

When an author submits a manuscript to Preventing Chronic Disease (PCD), the journal’s editors evaluate it for overall quality and appropriateness for the journal’s readership. Once cleared at this level, the manuscript undergoes confidential single-anonymous peer review.

The solicitation of a manuscript by PCD editors or others acting on PCD’s behalf (such as a guest editor) does not guarantee that it will be accepted for publication. The journal’s editor in chief makes final publication decisions. Editorial staff members edit accepted manuscripts for content, organization, grammar, style, format, and clarity before publication. Authors may offer suggestions on these edits but do not have right of refusal.

We are committed to evaluating and publishing articles promptly and to upholding the highest standards of ethical conduct. Manuscripts that express novel ideas of interest to a broad public health audience receive priority.

Overlapping or duplicate publication

Adapted from “Overlapping Publications” in Uniform Requirements for Manuscripts Submitted to Biomedical Journals, produced by the International Committee of Medical Journal Editors (ICMJE, or Vancouver Group).

Duplicate Submission
PCD is a primary-source periodical. We will not consider manuscripts that are simultaneously being considered by other journals, and we require authors to agree to an authorship statement that verifies that PCD is the only journal to which the authors have submitted their manuscript. Among the principal considerations that have led to this policy are: 1) the potential for disagreement when two (or more) journals claim the right to publish a manuscript that has been submitted simultaneously to more than one; and 2) the possibility that two or more journals will unknowingly and unnecessarily undertake the work of peer review, edit the same manuscript, and publish the same article.

However, PCD may decide to simultaneously or jointly publish an article if the editors believe that doing so would be in the best interest of public health.

Redundant Publication
Redundant (or duplicate) publication is publication of a paper that overlaps substantially with one already published in print or electronic media.

Readers of primary-source periodicals, whether print or electronic, deserve to be able to trust that what they are reading is original unless there is a clear statement that the author and editor are intentionally republishing an article. The bases of this position are international copyright laws, ethical conduct, and cost-effective use of resources. Duplicate publication of original research is particularly problematic, since it can result in inadvertent double counting or inappropriate weighting of the results of a single study, which distorts the available evidence.

The editors of PCD do not wish to receive manuscripts on work that has already been reported in large part in a published article or is contained in another paper that has been submitted or accepted for publication elsewhere, in print or in electronic media. This policy does not preclude the journal considering a manuscript that has been rejected by another journal, or a complete report that follows publication of a preliminary report, such as an abstract or poster displayed at a professional meeting. PCD does not consider results posted in clinical trial registries as previous publication if the results are presented in the registry in the form of a brief structured abstract or table. The Results registry should either cite the full publication or include a statement that indicates that the report has not been published in a peer-reviewed journal.

When submitting a manuscript, the author must make a complete statement to the editor about all submissions and previous reports (including meeting presentations and posting of results in registries) that might be regarded as redundant or duplicate publication. The author must alert the editor if the manuscript includes subjects about which the authors have published a previous report or have submitted a related report to another publication. Any such report must be referred to and referenced in the new manuscript. Copies of such material should be included with the submitted manuscript to help the editor decide how to handle the matter.

If redundant or duplicate publication is attempted or occurs without such notification, authors should expect editorial action to be taken. At the least, prompt rejection of the submitted manuscript should be expected. If the editor was not aware of the violations and the article has already been published, then a notice of redundant or duplicate publication will probably be published with or without the author’s explanation or approval. See Responding to Allegations of Possible Misconduct below.

Preliminary reporting to public media, governmental agencies, or manufacturers of scientific information described in a manuscript or a letter to the editor that has been accepted but not yet published violates the policy of PCD. See News Media Inquiries below.

Acceptable Secondary Publication
Certain types of articles, such as guidelines produced by governmental agencies and professional organizations, may need to reach the widest possible audience. In such instances, PCD editors may deliberately publish material that is also being published in other journals, with the agreement of the authors and the editors of those journals. Secondary publication for various other reasons, in the same or another language, especially in other countries, is justifiable and can be beneficial provided that the following conditions are met.

1. The authors have received approval from the editors of both journals; the editor concerned with secondary publication must have a photocopy, reprint, or manuscript of the primary version.
2. The priority of the primary publication is respected is specifically negotiated by both editors.
3. The manuscript for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
4. The secondary version faithfully reflects the data and interpretations of the primary version.
5. The footnote on the title page of the secondary version informs readers, peers, and documenting agencies that the manuscript has been published in whole or in part and states the primary reference. A suitable footnote might read, “This article is based on a study first reported in the [title of journal, with full reference].” Permission for such secondary publication should be free of charge.
6. The title of the secondary publication should indicate that it is a secondary publication (complete republication, abridged republication, complete translation, or abridged translation) of a primary publication. Of note, the NLM does not consider translations to be “republications” and does not cite or index translations when the original article was published in a journal that is indexed in MEDLINE.
7. Editors of journals that simultaneously publish in multiple languages should understand that NLM indexes the primary language version. When the full text of an article appears in more than one language in a journal issue (such as Canadian journals with the article in both English and French), both languages are indicated in the MEDLINE citation (for example, Mercer K. The relentless challenge in health care. Healthc Manage Forum. 2008 Summer;21(2):4-5. English, French. No abstract available. PMID:18795553).

 Top of Page

Authorship

PCD usually limits the number of authors to 10; any manuscript with more than 10 authors requires a description of the contributions of each author. We permit group authorship for large collaborations. Additional contributions may be attributed in the Acknowledgments section of the manuscript.

We follow the criteria for authorship detailed in ICMJE (http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html) beginning with the recommendation that all persons designated as authors should qualify for authorship, and all those who qualify should be listed. The 4 criteria for authorship defined by ICMJE are the following:

• Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
• Drafting the work or revising it critically for important intellectual content; AND
• Final approval of the version to be published; AND
• Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Individuals must fulfill all 4 conditions to qualify for authorship. General supervision, data collection, acquisition of funding, and substantial contributions to writing and editing are not grounds for authorship. Authors should recognize these participants in Acknowledgments, with participant permission.

All authors of a manuscript submitted to PCD must agree to its submission, take responsibility for its content, and agree in writing to any corrections or retractions. All parties must also agree in writing to changes in authorship (for example, adding or deleting names, or changing the order in which they appear in the byline) after the manuscript has been submitted. It is the responsibility of the corresponding author to ensure that the final proof is circulated to all coauthors for review and comment. The authorship statement, which the corresponding author must electronically sign, provides verification of the responsibilities claimed by the author. We may choose to publish explanations of specific author contributions along with articles.

Artificial Intelligence (AI)

PCD follows ICMJE recommendations on the use of artificial intelligence (AI) and assisted technology such as Large Language Models (LLMs), chatbots, or image creators in the development of work submitted to the journal. The use of any such technology in a submitted manuscript must be described in the cover letter and in the manuscript. Authorship cannot be assigned to Chatbots (such as ChatGPT) and other AI and AI-assisted technologies because those technologies cannot be responsible for the accuracy, integrity, and originality of the work. Authors must be able to assert that AI-produced text and images are not plagiarized and must ensure full attribution of all quoted material.

 Top of Page

Peer review

If PCD determines that a manuscript warrants peer review, it is assigned to 2 or more peer reviewers. Some papers may be assessed by statistical reviewers.

Peer reviews are conducted in strict confidentiality. We have a single-anonymous review process; authors are identified to reviewers, but reviewers remain anonymous to authors. We ask reviewers to give detailed comments (with references when possible) that would help authors to improve their manuscripts and PCD editors to decide whether to publish. For each manuscript reviewed, we ask reviewers to complete the Reviewer’s Confidential Manuscript Assessment for the Editor. Reviewers serve as advisors to PCD editors, who make final decisions.

We ask reviewers to disclose any conflicts of interest or personal or professional biases that may render them unable to provide a fair and objective assessment of the manuscript under review.

We welcome suggestions from authors for appropriate peer reviewers. The author online submission process provides the opportunity to list suggested reviewers.

 Top of Page

Conflicts of interest

PCD’s policy on conflicts of interest is based on guidance from the AMA Manual of Style, the International Committee of Medical Journal Editors, the Council of Science Editors, the Committee on Publication Ethics, and the World Association of Medical Editors. We require authors to disclose any and all financial, professional, or personal conflicts of interest in an accompanying cover letter. Details of this information remain confidential to the journal’s editors and are not provided to peer reviewers. We may, however, choose to disclose certain financial interests to readers on publication. Disclosure encompasses information about author affiliations that may potentially be regarded as having biased the research or results described in a manuscript. Financial conflicts include employment, salary, consulting fees, honoraria, stock or equity interests, expert testimony, and intellectual property rights (patent grants and pending applications for patent grants, royalties, and copyrights).

Authors are responsible for identifying all sources of funding for the work described in the manuscript and for including this information in 1) in the cover letter, 2) in ScholarOne when the manuscript is submitted, and 3) in the manuscript’s Acknowledgments section.

If any undisclosed conflicts or financial interests are identified after publication, we may choose to publish notices of failure to disclose such information.

We also ask reviewers to disclose any conflicts of interest and personal or professional biases that may render them unable to provide a fair and objective evaluation of the manuscript under review. Reviewers may wish to consult the editor in chief if they have any questions about such matters, and we ask reviewers to disqualify themselves if they consider themselves unable to give an impartial assessment.

 Top of Page

Access to manuscript data

By submitting a manuscript to PCD, authors agree to provide access to data that may be needed during the editorial and external peer review process both before and after publication, should questions arise during either time. Journal editorial staff and peer reviewers would use such data for the sole purpose of further evaluation. Failure to provide access to data will result in postponement of publication and/or overturn of the journal’s decision to accept the manuscript.

 Top of Page

Copyrights

The author hereby grants, transfers, and assigns to the US government for the full term of copyright and all extensions thereof the full and exclusive rights comprised in the copyright in and to the report, article, or other paper (the “work”) published by PCD and the material and contributions contained therein, any revised editions thereof and all derivative works based thereon, and all other proprietary rights thereto, in all languages and forms, and in all media of expression now known or later developed, throughout the world. The US government will commit the work to the public domain and allow it to be used and reproduced by anyone without permission. An author who includes materials that are copyrighted by a third party agrees to obtain written permission to ensure that the US government may place the work, including said material, in the public domain. If the work was funded by an National Institutes of health (NIH) grant, the author and US government agree that the author retains the rights necessary to provide the manuscript to (and for display by) PubMed Central. PCD will submit the final article for indexing in PubMed and PubMed Central. For more information on indexing see our FAQs page.

 Top of Page

Permissions

Authors must obtain written permissions in these 4 situations:

• Publishers of figures, tables, or survey instruments or tools included in the manuscript and previously published (or adapted from previously published figures, or tables, or survey instruments or tools) must provide signed consent to the authors to publish this information in PCD.
• Persons identifiable in photographs, case descriptions, or pedigrees must provide signed consent to the authors to be identified in the manuscript.
• Persons named as having provided information through personal communication (oral or written, including conversations, letters, e-mails, and telephone calls) must provide signed consent to the authors to be included in the manuscript, and they must declare in writing that the information is accurate.
• Persons acknowledged in the manuscript must provide signed consent to the authors to be acknowledged.

Corresponding authors are responsible for maintaining these written permissions and making them available to the editors at PCD on request.

 Top of Page

Use of human subjects or animals

Manuscripts that describe projects involving human or animal subjects must indicate clearly in the Methods section that the appropriate ethics committee or institutional review board approved the project. For investigations involving human subjects, state also in the Methods section the manner in which adult subjects and parents or legal guardians of minors or incapacitated adults provided informed consent.

 Top of Page

Distinguishing between errors and research misconduct

PCD follows AMA guidelines to distinguish between errors and research misconduct; AMA guidelines are based on the current common definition of research misconduct from US Department of Health and Human Services (http://ori.hhs.gov/sites/default/files/42_cfr_parts_50_and_93_2005.pdf  [PDF – 300 KB]):

As noted in AMA: https://academic.oup.com/mit-press-scholarship-online/book/20079

Research misconduct is defined as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.

Fabrication is making up data or results and recording or reporting them.

Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.

Plagiarism is the appropriation of another person’s ideas, processes, results, or words without giving appropriate credit.

Research misconduct does not include honest error or differences of opinion. A finding of research misconduct requires that:

• there be a significant departure from accepted practices of the relevant research community; and
• the misconduct be committed intentionally, or knowingly, or recklessly; and
• the allegation be proven by a preponderance of evidence.

None of the definitions of scientific misconduct include honest error or differences in interpretation. Nor do they include or pertain to violations of human or animal experimentation requirements, financial mismanagement/misconduct, or other acts covered by existing laws, such as sexual harassment, copyright, confidentiality, libel, or other concerns, such as authorship disputes, duplicate publication, self-plagiarism without indication of one’s previous work, or conflicts of interest.

 Top of Page

Errors

Our policy is to correct mistakes within the electronic text of the article as soon as we know of them. We note within the corrected article that a correction has been made, and we note the date it was made. In the issue immediately following the correction, we detail the error in our Errata section and link the notice of error to the original article. Any disagreements with authors or others on what constitutes errata are referred to the editor in chief or his or her designee.

 Top of Page

Responding to allegations of possible misconduct

Based on AMA (www.amamanualofstyle.com) and WAME, Publication Ethics Policies for Medical Journals (www.wame.org)

Definitions of Misconduct
PCD follows AMA’s definition of misconduct, including the distinction between misconduct and honest or unintentional error, as noted (see AMA 5.4):
Research misconduct is defined as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.
Fabrication is making up data or results and recording or reporting them.
Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.
Plagiarism is the appropriation of another person’s ideas, processes, results, or words without giving appropriate credit.
Research misconduct does not include honest error or differences of opinion. A finding of research misconduct requires that:

• there be a significant departure from accepted practices of the relevant research community; and
• the misconduct be committed intentionally, or knowingly, or recklessly; and
• the allegation be proven by a preponderance of evidence

None of the definitions of scientific misconduct include honest error or differences in interpretation. Nor do they include or pertain to violations of human or animal experimentation requirements (see AMA 5.8, Protecting Research Participants’ and Patients’ Rights in Scientific Publication), financial mismanagement/misconduct, or other acts covered by existing laws, such as sexual harassment, copyright, confidentiality, libel (see AMA 5.6.3, Intellectual Property: Ownership, Access, Rights, and Management, Copyright: Definition, History, and Current Law; 5.7, Confidentiality; and 5.9, Defamation, Libel), or other concerns, such as authorship disputes, duplicate publication, self-plagiarism without indication of one’s previous work, or conflicts of interest (see AMA 5.1, Authorship Responsibility; 5.3, Duplicate Publication; and 5.5, Conflicts of Interest).

The most common forms of scientific misconduct include (the following are taken with minor modification from the Office of Research Integrity publication Analysis of Institutional Policies for Responding to Allegations of Scientific Misconduct, http://ori.hhs.gov/documents/institutional_policies.pdf, p. 17, accessed 01/27/10): [PDF – 473 KB]

• Falsification of data: ranges from fabrication to deceptive selective reporting of findings and omission of conflicting data, or willful suppression and/or distortion of data.
• Plagiarism: The appropriation of the language, ideas, or thoughts of another without crediting their true source, and representation of them as one’s own original work.
• Improprieties of authorship: Improper assignment of credit, such as excluding others, misrepresentation of the same material as original in more than one publication, inclusion of individuals as authors who have not made a contribution to the work published; or submission of multiauthored publications without the concurrence of all authors.
• Misappropriation of the ideas of others: an important aspect of scholarly activity is the exchange of ideas among colleagues. Scholars can acquire novel ideas from others during the process of reviewing grant applications and manuscripts. However, improper use of such information can constitute fraud. Wholesale appropriation of such material constitutes misconduct.
• Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results.
• Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials.
• Inappropriate behavior in relation to misconduct: this includes unfounded or knowingly false accusations of misconduct, failure to report known or suspected misconduct, withholding or destruction of information relevant to a claim of misconduct and retaliation against persons involved in the allegation or investigation.

Deliberate misrepresentation of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement is included.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the journal, and this fact reported to their institution.

 Top of Page

Opinions and endorsements

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

 Top of Page

Open Access Statement

PCD is an open access journal which means that all content is freely available without charge to the user or their institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.

 Top of Page